Congratulations, you’ve made it! After years of R&D, clinical trials, and regulatory submissions, your small biotech has finally secured its first commercial product approval. The hard work is done, right? Not so fast.
As you pivot from a development-focused organization to a commercial one, a new and critical function takes center stage: Medical Information. This team is the primary source for accurate, unbiased, and compliant scientific information about your product for healthcare professionals (HCPs), patients, and the public.
For a small biotech, launching this function can feel like a daunting new challenge, particularly because many of the compliance rules are different from the GxP regulations you’ve lived and breathed. Here are some of the most common and dangerous compliance pitfalls to avoid as you build your medical information portfolio.
Pitfall #1: The “We’ll Just Do It Ad-Hoc” Approach
In the early days, with a small team and limited inquiries, it’s tempting to handle medical information requests (MIRs) as they come in. A quick email, a phone call, maybe a shared spreadsheet. This is a ticking time bomb.
The Solution: Establish a formal, documented process from day one. You need a robust Standard Operating Procedure (SOP) that outlines:
- The intake process for all inquiries (phone, email, web).
- A clear triaging system for medical questions, adverse events (AEs), and product complaints (PCs).
- Standardized response templates to ensure consistency and accuracy.
- A strict documentation and archiving protocol for every single inquiry and response.
Without this, you have no audit trail. When a regulator asks to see how you handled a specific request, a pile of emails or a messy spreadsheet won’t cut it.
Pitfall #2: The Off-Label Minefield
Your first product is a scientific breakthrough, and the data is exciting. HCPs and researchers will naturally be curious about unapproved uses, dosage regimens, or patient populations. This is the single biggest area of compliance risk for a medical information team.
The Solution: Implement a watertight policy for handling off-label inquiries. While HCPs can legally prescribe a product for unapproved uses, a manufacturer is strictly prohibited from proactively promoting such uses. Your Med Info team must be trained to:
- Differentiate between a solicited request (a direct question about off-label use) and an unsolicited one (a general question that could lead to an off-label discussion).
- Provide only truthful, non-misleading, and balanced information.
- Stick to a pre-approved response for off-label inquiries, which often involves providing the approved product label and a statement that the company does not have data to support the unapproved use.
- Avoid engaging in any promotional language or activities.
This is a fine line to walk, and a single misstep can lead to severe regulatory scrutiny, fines, and reputational damage.
Pitfall #3: Failure to Connect the Dots on Safety Reporting
Your Med Info team is a crucial front line for pharmacovigilance (PV). An inquiry from an HCP or patient may contain a critical adverse event (AE) or a product complaint (PC). The failure to properly identify and escalate these events is a major regulatory violation.
The Solution: Your SOP must include a clear, unambiguous process for identifying AEs and PCs. The training for your Med Info team should be intensive on this point.
- What constitutes an AE? What is a PC?
- How should an AE be documented and what data needs to be captured?
- What are the strict timelines for escalating these events to the PV and Quality teams? (For example, within one business day).
The process needs to be seamless and fail-safe. Using a shared, validated database that automatically alerts the correct teams is a best practice that mitigates this risk.
Pitfall #4: Underestimating the Power of Data Privacy
Inquiries often contain sensitive information, including protected health information (PHI) about patients. As a small biotech, you may not have a dedicated data privacy or cybersecurity team, but compliance with regulations like HIPAA and GDPR is non-negotiable.
The Solution:
- Develop clear policies for the collection, storage, and disposal of all data that contains personal identifiers.
- Ensure your IT infrastructure is secure and that any medical information database is validated and access-controlled.
- Provide mandatory data privacy and security training to the entire Med Info team.
- Be transparent in your data collection forms and website privacy policies about how you will use and protect the information provided.
Pitfall #5: The “We’re Too Small for That” Mentality
One of the biggest mistakes a small biotech can make is assuming that regulatory authorities will be lenient because of its size. The reality is the opposite. Regulators expect the same level of compliance from a small company as they do from a multinational pharma giant. A compliance failure from a small company can have disproportionately severe consequences, including a delayed product launch, a recall, or even the inability to market the drug.
The Solution:
- Invest in expertise. If you don’t have the in-house compliance staff, work with a consulting partner.
- Build scalable systems. Choose technology and processes that can grow with you.
- Embrace a culture of compliance. This starts at the top. Ensure your executive team understands the importance of a robust Med Info function and allocates the necessary resources.
Launching your first commercial product is a moment to celebrate. But as you transition, building a compliant and well-run Medical Information function isn’t just a requirement—it’s a foundation for long-term success, patient safety, and corporate integrity.
